Literature DB >> 1911227

Influence of the antioestrogen tamoxifen on normal breast tissue.

K J Walker1, J M Price-Thomas, W Candlish, R I Nicholson.   

Abstract

Immunohistochemical assays have been employed to study the expression of ER, PgR, EGFR and Ki67 immunostaining in normal breast tissue (n = 76). The expression of ER and PgR was highly variable in both pre and postmenopausal women and was characterised by large numbers of apparently negative cells. This was most evident for ER-ICA staining in tissues removed from premenopausal women. PgR levels were highest in the ducts of premenopausal women, while EGFR expression was elevated in both ducts and lobules. Ki67 expression was observed in less than 10% of all normal cells and was suppressed by the menopause in lobular tissue. Tamoxifen therapy (40 mg d-1) did not influence the expression of PgR, EGFR or Ki67 immunostaining in cancer associated normal tissue (n = 17). A significant increase, however, was observed in the mean percentage ER positivity in ductal tissue. No effect of duration of tamoxifen therapy was observed on the expression of the antigens studied.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911227      PMCID: PMC1977690          DOI: 10.1038/bjc.1991.395

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.

Authors:  J Gerdes; R J Lelle; H Pickartz; W Heidenreich; R Schwarting; L Kurtsiefer; G Stauch; H Stein
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

2.  Immunocytochemical localization of estrogen receptor in human breast tissue.

Authors:  K J Walker; N Bouzubar; J Robertson; I O Ellis; C W Elston; R W Blamey; D W Wilson; K Griffiths; R I Nicholson
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

3.  Transforming growth factor alpha in human mammary carcinomas and their metastases.

Authors:  A Macias; R Perez; T Hägerström; L Skoog
Journal:  Anticancer Res       Date:  1989 Jan-Feb       Impact factor: 2.480

4.  Immunohistochemical localization of epidermal growth factor in rat and man.

Authors:  S S Poulsen; E Nexø; P S Olsen; J Hess; P Kirkegaard
Journal:  Histochemistry       Date:  1986

5.  Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

Authors:  J R Sainsbury; J R Farndon; G K Needham; A J Malcolm; A L Harris
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

6.  Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer.

Authors:  J R Sainsbury; J R Farndon; G V Sherbet; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

7.  Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues.

Authors:  A G Kasselberg; D N Orth; M E Gray; M T Stahlman
Journal:  J Histochem Cytochem       Date:  1985-04       Impact factor: 2.479

8.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

Authors:  N Bouzubar; K J Walker; K Griffiths; I O Ellis; C W Elston; J F Robertson; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

9.  LHRH agonists and the prevention of breast and ovarian cancer.

Authors:  M C Pike; R K Ross; R A Lobo; T J Key; M Potts; B E Henderson
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

10.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; G M Farrington; D Cosgrove; J B Davey; M Dowsett; J A McKinna; A G Nash; H D Sinnett
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

View more
  10 in total

Review 1.  Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?

Authors:  M O'Brien; T J Powles
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

2.  Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Authors:  David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; William Dooley; Alexander Miller; David Flockhart; Cheryl Lewis
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-21

Review 3.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Authors:  R I Nicholson; R A McClelland; J M Gee; D L Manning; P Cannon; J F Robertson; I O Ellis; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

5.  The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines.

Authors:  A K Sharma; K Horgan; R A McClelland; A G Douglas-Jones; T Van Agthoven; L C Dorssers; R I Nicholson
Journal:  Histochem J       Date:  1994-04

Review 7.  Model of tumor-associated epigenetic changes of HER2, ER, and PgR expression in invasive breast cancer phenotypes.

Authors:  Sven Kurbel
Journal:  Tumour Biol       Date:  2013-05-03

Review 8.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Authors:  R I Nicholson; J M Gee
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex.

Authors:  Suhong Yu; Xingtian Yang; Yewei Zhu; Fangwei Xie; Yusheng Lu; Ting Yu; Cuicui Yan; Jingwei Shao; Yu Gao; Fan Mo; Guoneng Cai; Patrick J Sinko; Lee Jia
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

10.  Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.

Authors:  D F Hargreaves; F Knox; R Swindell; C S Potten; N J Bundred
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.